Dexcom will stop producing G6 CGM sensors July 1, 2026, urging patients to switch to the smaller, more accurate G7 model.
Barclays analyst Matt Miksic lowered the firm’s price target on DexCom (DXCM) to $92 from $113 and keeps an Equal Weight rating on the shares. The firm says its 2025 medical technology outlook “hinges ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results